vs
Side-by-side financial comparison of CMB.TECH NV (CMBT) and QuidelOrtho Corp (QDEL). Click either name above to swap in a different company.
QuidelOrtho Corp is the larger business by last-quarter revenue ($619.8M vs $592.8M, roughly 1.0× CMB.TECH NV). CMB.TECH NV runs the higher net margin — 32.3% vs -14.8%, a 47.1% gap on every dollar of revenue. On growth, QuidelOrtho Corp posted the faster year-over-year revenue change (-10.5% vs -34.6%).
CMB.TECH, before October 2024 known as Euronav, is a crude oil tanker transport company, which consists of VLCCs, Suezmaxes and FSOs.
QuidelOrtho Corporation is an American manufacturer of diagnostic healthcare products that are sold worldwide.
CMBT vs QDEL — Head-to-Head
Income Statement — Q4 FY2024 vs Q1 FY2027
| Metric | | |
|---|---|---|
| Revenue | $592.8M | $619.8M |
| Net Profit | $191.2M | $-91.8M |
| Gross Margin | — | — |
| Operating Margin | 46.4% | — |
| Net Margin | 32.3% | -14.8% |
| Revenue YoY | -34.6% | -10.5% |
| Net Profit YoY | -63.3% | — |
| EPS (diluted) | $1.01 | $-1.35 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $619.8M | ||
| Q3 25 | — | $699.9M | ||
| Q2 25 | — | $613.9M | ||
| Q1 25 | — | $692.8M | ||
| Q4 24 | $592.8M | $707.8M | ||
| Q3 24 | — | $727.1M | ||
| Q2 24 | — | $637.0M | ||
| Q1 24 | — | $711.0M |
| Q1 26 | — | $-91.8M | ||
| Q3 25 | — | $-733.0M | ||
| Q2 25 | — | $-255.4M | ||
| Q1 25 | — | $-12.7M | ||
| Q4 24 | $191.2M | $-178.4M | ||
| Q3 24 | — | $-19.9M | ||
| Q2 24 | — | $-147.7M | ||
| Q1 24 | — | $-1.7B |
| Q1 26 | — | — | ||
| Q3 25 | — | -100.7% | ||
| Q2 25 | — | -29.4% | ||
| Q1 25 | — | 4.7% | ||
| Q4 24 | 46.4% | -14.2% | ||
| Q3 24 | — | 2.1% | ||
| Q2 24 | — | -18.4% | ||
| Q1 24 | — | -247.3% |
| Q1 26 | — | -14.8% | ||
| Q3 25 | — | -104.7% | ||
| Q2 25 | — | -41.6% | ||
| Q1 25 | — | -1.8% | ||
| Q4 24 | 32.3% | -25.2% | ||
| Q3 24 | — | -2.7% | ||
| Q2 24 | — | -23.2% | ||
| Q1 24 | — | -239.9% |
| Q1 26 | — | $-1.35 | ||
| Q3 25 | — | $-10.78 | ||
| Q2 25 | — | $-3.77 | ||
| Q1 25 | — | $-0.19 | ||
| Q4 24 | $1.01 | $-2.54 | ||
| Q3 24 | — | $-0.30 | ||
| Q2 24 | — | $-2.20 | ||
| Q1 24 | — | $-25.50 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $38.9M | $140.4M |
| Total DebtLower is stronger | $2.6B | $2.5B |
| Stockholders' EquityBook value | $1.2B | $1.9B |
| Total Assets | $3.9B | $5.6B |
| Debt / EquityLower = less leverage | 2.20× | 1.33× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $140.4M | ||
| Q3 25 | — | $98.1M | ||
| Q2 25 | — | $151.7M | ||
| Q1 25 | — | $127.1M | ||
| Q4 24 | $38.9M | $98.3M | ||
| Q3 24 | — | $143.7M | ||
| Q2 24 | — | $107.0M | ||
| Q1 24 | — | $78.5M |
| Q1 26 | — | $2.5B | ||
| Q3 25 | — | $2.5B | ||
| Q2 25 | — | $2.1B | ||
| Q1 25 | — | $2.1B | ||
| Q4 24 | $2.6B | $2.1B | ||
| Q3 24 | — | $2.2B | ||
| Q2 24 | — | $2.2B | ||
| Q1 24 | — | $2.2B |
| Q1 26 | — | $1.9B | ||
| Q3 25 | — | $2.0B | ||
| Q2 25 | — | $2.8B | ||
| Q1 25 | — | $3.0B | ||
| Q4 24 | $1.2B | $3.0B | ||
| Q3 24 | — | $3.2B | ||
| Q2 24 | — | $3.2B | ||
| Q1 24 | — | $3.3B |
| Q1 26 | — | $5.6B | ||
| Q3 25 | — | $5.7B | ||
| Q2 25 | — | $6.4B | ||
| Q1 25 | — | $6.5B | ||
| Q4 24 | $3.9B | $6.4B | ||
| Q3 24 | — | $6.8B | ||
| Q2 24 | — | $6.7B | ||
| Q1 24 | — | $6.7B |
| Q1 26 | — | 1.33× | ||
| Q3 25 | — | 1.23× | ||
| Q2 25 | — | 0.74× | ||
| Q1 25 | — | 0.70× | ||
| Q4 24 | 2.20× | 0.72× | ||
| Q3 24 | — | 0.68× | ||
| Q2 24 | — | 0.70× | ||
| Q1 24 | — | 0.68× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $204.4M | — |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | 1.07× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q3 25 | — | $-45.5M | ||
| Q2 25 | — | $-46.8M | ||
| Q1 25 | — | $65.6M | ||
| Q4 24 | $204.4M | $63.7M | ||
| Q3 24 | — | $117.9M | ||
| Q2 24 | — | $-97.9M | ||
| Q1 24 | — | $-700.0K |
| Q1 26 | — | — | ||
| Q3 25 | — | $-94.7M | ||
| Q2 25 | — | $-84.3M | ||
| Q1 25 | — | $9.4M | ||
| Q4 24 | — | $16.5M | ||
| Q3 24 | — | $71.4M | ||
| Q2 24 | — | $-133.2M | ||
| Q1 24 | — | $-66.8M |
| Q1 26 | — | — | ||
| Q3 25 | — | -13.5% | ||
| Q2 25 | — | -13.7% | ||
| Q1 25 | — | 1.4% | ||
| Q4 24 | — | 2.3% | ||
| Q3 24 | — | 9.8% | ||
| Q2 24 | — | -20.9% | ||
| Q1 24 | — | -9.4% |
| Q1 26 | — | — | ||
| Q3 25 | — | 7.0% | ||
| Q2 25 | — | 6.1% | ||
| Q1 25 | — | 8.1% | ||
| Q4 24 | — | 6.7% | ||
| Q3 24 | — | 6.4% | ||
| Q2 24 | — | 5.5% | ||
| Q1 24 | — | 9.3% |
| Q1 26 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 1.07× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CMBT
Segment breakdown not available.
QDEL
| Labs | $353.1M | 57% |
| Immunohematology | $138.3M | 22% |
| Point of Care | $112.8M | 18% |
| Molecular Diagnostics | $7.8M | 1% |
